Second Alzheimer's drug can slow disease by a few months
Another experimental Alzheimers drug can modestly slow patients inevitable worsening — by about four to seven months, researchers reported Monday.
Source: pantagraph.com
📰 Mark Mintun News
Page 12 - Mark Mintun News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mark Mintun. Real-time updates on events, politics, business and more.
Eli Lilly's Alzheimer's drug donanemab can slow disease: Study
Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.
Source: wwltv.com
Second Alzheimer's drug can slow disease by a few months
Another experimental Alzheimers drug can modestly slow patients inevitable worsening — by about four to seven months, researchers reported Monday.
Source: journaltimes.com
Eli Lilly's Alzheimer's drug donanemab can slow disease: Study
Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.
Source: ksdk.com
Second Alzheimer's drug can slow disease by a few months
Another experimental Alzheimers drug can modestly slow patients inevitable worsening — by about four to seven months, researchers reported Monday.
Source: qconline.com
Second Alzheimer's drug can slow disease by a few months
Another experimental Alzheimers drug can modestly slow patients inevitable worsening — by about four to seven months, researchers reported Monday.
Source: bismarcktribune.com
Eli Lilly's Alzheimer's drug donanemab can slow disease: Study
Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.
Source: kagstv.com
Drug success offers hope of finding 'cure' for dementia
EXCLUSIVE: A new drug has been shown to slow the rate at which memory and thinking skills decline.
Source: express.co.uk
Alzheimer's drug slows cognitive decline by 35%, says manufacturer - The Pharmaceutical Journal
The Pharmaceutical Journal from the Royal Pharmaceutical Society
Ian Maidment Mark Mintun Susan Kohlhaas Alzheimer Research United Kingdom Aston University Association International Conference
Source: pharmaceutical-journal.com
Cognitive decline slowed in Alzheimer's drug trial
The phase 3 drug trial from Eli Lilly and Company indicated significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's.
Source: labonline.com.au